Share This Author
Establishment of new preparation method for solid dispersion formulation of tacrolimus.
Development of a Novel Drug Release System, Time-Controlled Explosion System (TES). III. Relation between Lag Time and Membrane
To describe lag time of Time-Controlled Explosion System (TES), the system's water absorption kinetics was investigated. Study of water absorption in TES with EC membrane revealed the following…
Development of novel sustained-release system, disintegration-controlled matrix tablet (DCMT) with solid dispersion granules of nilvadipine (II): in vivo evaluation.
The Site-Specific Transport and Metabolism of Tacrolimus in Rat Small Intestine
- S. Tamura, Y. Tokunaga, R. Ibuki, G. Amidon, H. Sezaki, S. Yamashita
- Biology, MedicineJournal of Pharmacology and Experimental…
- 1 July 2003
It is concluded that the site-dependent differences in P-gp and/or P450 activity could be the prime cause of large intra- and interindividual variability in the oral absorption of tacrolimus.
Development of a Novel Drug Release System, Time-Controlled Explosion System (TES). II. Design of Multiparticulate TES and in Vitro Drug Release Properties
For the design of multiparticulate Time-Controlled Explosion System (TES), the thickness of the swelling agent layer was optimized by determining the amount of drug released. Low-substituted…
Bone-specific delivery and sustained release of diclofenac, a non-steroidal anti-inflammatory drug, via bisphosphonic prodrug based on the Osteotropic Drug Delivery System (ODDS).
Development of novel sustained-release system, disintegration-controlled matrix tablet (DCMT) with solid dispersion granules of nilvadipine.
In vivo performance of time-controlled explosion system (TES) in GI physiology regulated dogs
Osteotropic drug delivery system (ODDS) based on bisphosphonic prodrug. V. Biological disposition and targeting characteristics of osteotropic estradiol.
- J. Fujisaki, Y. Tokunaga, T. Takahashi, S. Kimura, F. Shimojo, T. Hata
- Biology, MedicineBiological & pharmaceutical bulletin
- 15 November 1997
Results suggest that ODDS has a potential to improve not only the apparent potency but also the therapeutic index of E2, and should improve patient compliance with lower adverse effects and less frequent medication in long-term estrogen replacement therapy.
Osteotropic drug delivery system (ODDS) based on bisphosphonic prodrug. I.v. effects of osteotropic estradiol on bone mineral density and uterine weight in ovariectomized rats.
- J. Fujisaki, Y. Tokunaga, T. Takahashi, F. Shimojo, S. Kimura, T. Hata
- Biology, ChemistryJournal of drug targeting
In vitro bone resorption analysis revealed that E2-BP exhibits antiresorptive activity not as a bisphosphonate but as a prodrug of E2, demonstrating that E 2-BP has the potential to improve patient compliance in estrogen therapy by its minimal adverse effects and less frequent medication.